Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Nov;35(11):2262–2266. doi: 10.1128/aac.35.11.2262

Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.

F S Stals 1, E de Clercq 1, C A Bruggeman 1
PMCID: PMC245369  PMID: 1666493

Abstract

Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [DHPG], were evaluated for their inhibitory effects on human cytomegalovirus (HCMV) replication in human embryonal fibroblasts and on rat cytomegalovirus (RCMV) replication in rat embryonal fibroblasts. The concentrations of HPMPC or DHPG required to inhibit HCMV plaque formation by 50% were 0.1 and 0.6 micrograms/ml, respectively. For RCMV, these values were 1.1 and 25 micrograms/ml, respectively. For HCMV, the selectivity indices of HPMPC and DHPG, as determined by the ratio of the 50% inhibitory concentration for cell growth to the 50% inhibitory concentration for virus plaque formation, were 1,250 and 140, respectively, and for RCMV, they were 500 and 76, respectively. HPMPC was far more active than DHPG against RCMV infection in vivo as measured by mortality, histopathological changes, and virus titers in organs of immunocompromised RCMV-infected rats. The minimal effective dosage required to prevent mortality from RCMV infection was a single dose of HPMPC at 2 mg/kg of body weight compared with DHPG therapy twice daily at 20 mg/kg/day for 5 days. Furthermore, HPMPC was more effective than DHPG in reducing virus titers in internal organs (P less than 0.01) and in RCMV-induced histopathologic lesions. In contrast to DHPG, which did not show activity when administered 1 day before infection, HPMPC was effective even when administered 7 days before RCMV infection.

Full text

PDF
2264

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bronson J. J., Ghazzouli I., Hitchcock M. J., Webb R. R., 2nd, Martin J. C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem. 1989 Jul;32(7):1457–1463. doi: 10.1021/jm00127a010. [DOI] [PubMed] [Google Scholar]
  2. Bruggeman C. A., Meijer H., Bosman F., van Boven C. P. Biology of rat cytomegalovirus infection. Intervirology. 1985;24(1):1–9. doi: 10.1159/000149612. [DOI] [PubMed] [Google Scholar]
  3. Bruggeman C. A., Meijer H., Dormans P. H., Debie W. M., Grauls G. E., van Boven C. P. Isolation of a cytomegalovirus-like agent from wild rats. Arch Virol. 1982;73(3-4):231–241. doi: 10.1007/BF01318077. [DOI] [PubMed] [Google Scholar]
  4. Bruning J. H., Debie W. H., Dormans P. H., Meijer H., Bruggeman C. A. The development and characterization of monoclonal antibodies against rat cytomegalovirus induced antigens. Arch Virol. 1987;94(1-2):55–70. doi: 10.1007/BF01313725. [DOI] [PubMed] [Google Scholar]
  5. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P. C. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2;323(6087):464–467. doi: 10.1038/323464a0. [DOI] [PubMed] [Google Scholar]
  6. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987 Dec;8(5-6):261–272. doi: 10.1016/s0166-3542(87)80004-9. [DOI] [PubMed] [Google Scholar]
  7. Holý A., Votruba I., Merta A., Cerný J., Veselý J., Vlach J., Sedivá K., Rosenberg I., Otmar M., Hrebabecký H. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res. 1990 Jun;13(6):295–311. doi: 10.1016/0166-3542(90)90014-x. [DOI] [PubMed] [Google Scholar]
  8. Li S. B., Yang Z. H., Feng J. S., Fong C. K., Lucia H. L., Hsiung G. D. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 1990 May;13(5):237–252. doi: 10.1016/0166-3542(90)90069-j. [DOI] [PubMed] [Google Scholar]
  9. Macher A. M., Reichert C. M., Straus S. E., Longo D. L., Parrillo J., Lane H. C., Fauci A. S., Rook A. H., Manischewitz J. F., Quinnan G. V., Jr Death in the AIDS patient: role of cytomegalovirus. N Engl J Med. 1983 Dec 8;309(23):1454–1454. doi: 10.1056/NEJM198312083092312. [DOI] [PubMed] [Google Scholar]
  10. Meijer H., Dormans P. H., Geelen J. L., van Boven C. P. Rat cytomegalovirus: studies on the viral genome and the proteins of virions and nucleocapsids. J Gen Virol. 1984 Apr;65(Pt 4):681–695. doi: 10.1099/0022-1317-65-4-681. [DOI] [PubMed] [Google Scholar]
  11. Quinnan G. V., Jr, Masur H., Rook A. H., Armstrong G., Frederick W. R., Epstein J., Manischewitz J. F., Macher A. M., Jackson L., Ames J. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA. 1984 Jul 6;252(1):72–77. [PubMed] [Google Scholar]
  12. Snoeck R., Sakuma T., De Clercq E., Rosenberg I., Holy A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 1988 Dec;32(12):1839–1844. doi: 10.1128/aac.32.12.1839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Votruba I., Bernaerts R., Sakuma T., De Clercq E., Merta A., Rosenberg I., Holý A. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol Pharmacol. 1987 Oct;32(4):524–529. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES